Legend Biotech Corporation is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
“This new facility underscores Legend’s commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partnerships with local, leading research institutions. We look forward to bolstering our cell therapy capabilities at this new site.”
The new Philadelphia facility adds to Legend’s existing global R&D organization, which encompasses more than 350 employees across the globe. The 31,000-square-foot facility at 2300 Market Street is expected to be complete in the third quarter of 2025. Legend, which has over 1,200 employees in the United States, anticipates 55 full-time employees will eventually be based in the Philadelphia facility. This expansion builds on Legend’s existing R&D footprint in the U.S., including a facility in Piscataway, New Jersey.
“Legend’s investment in this new site will offer our world-class research team an optimal environment and resources to expand on our cutting-edge innovation,” said Guowei Fang, Ph.D., Chief Scientific Officer and Head of Business Development of Legend Biotech. “We are particularly enthusiastic about the proximity to leading academic institutions in Philadelphia that are at the forefront of medical breakthroughs as we focus on advancing our sustainable pipeline of innovative cell therapies.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!